Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Edna Cukierman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1452-9576; OpenAlex author ID A5038454044. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
99
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 4 papers

Papers 20

  1. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  2. ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression. Co-author DOI 10.1038/s43018-026-01265-5↗
  3. Autophagy inhibition in pancreatic cancer: hope or hype? First author DOI 10.1080/27694127.2026.2721748↗
  4. A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer Co-author DOI 10.64898/2026.05.20.726559↗
  5. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01188-x↗
  6. Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Co-author DOI 10.1016/j.celrep.2024.114972↗
  7. Pulsed low-dose-rate radiation (PLDR) reduces the tumor-promoting responses induced by conventional chemoradiation in pancreatic cancer-associated fibroblasts Last author DOI 10.1101/2024.01.13.575510↗
  8. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer Last author DOI 10.1101/2024.05.15.594354↗
  9. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Co-author DOI 10.1158/0008-5472.can-24-2860↗
  10. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0547↗
  11. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-22-0602↗
  12. NetrinG1+ cancer-associated fibroblasts generate unique extracellular vesicles that support the survival of pancreatic cancer cells under nutritional stress. Last author DOI 10.1158/2767-9764.crc-21-0147↗
  13. Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition. First author DOI 10.1186/s12885-022-10330-y↗
  14. Palladin isoforms 3 and 4 regulate cancer-associated fibroblast pro-tumor functions in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-021-82937-3↗
  15. Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2020.03.020↗
  16. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.08.015↗
  17. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  18. Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Last author DOI 10.1016/j.matbio.2018.11.001↗
  19. Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2016.146↗
  20. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. Co-author DOI 10.1186/1471-2407-11-245↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Janusz Franco‐Barraza · 13 shared papers, 2011–2026 · strength 1.66
  2. Igor A. Astsaturov · 5 shared papers, 2020–2026 · strength 1.04
  3. Debora Barbosa Vendramini Costa · 6 shared papers, 2021–2026 · strength 1.03
  4. Tiffany Luong · 5 shared papers, 2022–2026 · strength 1.01
  5. Ralph A. Francescone III · 6 shared papers, 2020–2026 · strength 0.89
  6. Charline Ogier · 4 shared papers, 2020–2026 · strength 0.55
  7. Nina G. Steele · 3 shared papers, 2023–2026 · strength 0.54
  8. Kristopher S. Raghavan · 3 shared papers, 2021–2024 · strength 0.47
  9. Efrat Dotan · 2 shared papers, 2025–2026 · strength 0.44
  10. Emma Guilbaud · 1 shared paper, 2026 · strength 0.43
  11. Lorenzo Galluzzi · 1 shared paper, 2026 · strength 0.43
  12. Joshua E. Meyer · 2 shared papers, 2024–2025 · strength 0.42
  13. Kathryn E. Maraszek · 2 shared papers, 2023–2026 · strength 0.38
  14. Michael E. Feigin · 2 shared papers, 2023–2026 · strength 0.38
  15. Marina Pasca di Magliano · 2 shared papers, 2020–2024 · strength 0.34
  16. Serge Y Fuchs · 2 shared papers, 2023–2026 · strength 0.32
  17. Ben Z. Stanger · 2 shared papers, 2023–2024 · strength 0.32
  18. Mara H. Sherman · 2 shared papers, 2020–2024 · strength 0.31
  19. Anirban Maitra · 2 shared papers, 2020–2024 · strength 0.31
  20. Linara Gabitova-Cornell · 2 shared papers, 2020–2026 · strength 0.26
  21. Erica A. Golemis · 2 shared papers, 2020–2026 · strength 0.26
  22. Vinod P. Balachandran · 1 shared paper, 2026 · strength 0.24
  23. Miriam Klauß · 1 shared paper, 2026 · strength 0.24
  24. Thierry Conroy · 1 shared paper, 2026 · strength 0.24
  25. Susanne Roth · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.